Scarica l'app Stockscreener
6.31
0.94%
-0.06
Dopo l'orario di chiusura:
6.31
Precedente Chiudi:
$6.37
Aprire:
$6.3
Volume 24 ore:
425.99K
Relative Volume:
0.65
Capitalizzazione di mercato:
$451.57M
Reddito:
$1,000.00K
Utile/perdita netta:
$-48.81M
Rapporto P/E:
-8.1556
EPS:
-0.7737
Flusso di cassa netto:
$-39.95M
1 W Prestazione:
+3.44%
1M Prestazione:
+56.19%
6M Prestazione:
+176.75%
1 anno Prestazione:
+434.75%
Intervallo 1D:
$6.26
$6.8095
Intervallo di 1 settimana:
$5.75
$6.8095
Portata 52W:
$0.6922
$6.8095
Shattuck Labs Inc Stock (STTK) Company Profile
Nome
Shattuck Labs Inc
Settore
Industria
Telefono
512-900-4690
Indirizzo
500 W. 5TH STREET, AUSTIN
Compare STTK vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
6.31 | 455.86M | 1,000.00K | -48.81M | -39.95M | -0.7737 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-06 | Ripresa | Needham | Buy |
| 2026-01-28 | Iniziato | Piper Sandler | Overweight |
| 2025-12-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-09-08 | Iniziato | Wedbush | Outperform |
| 2025-03-17 | Iniziato | Leerink Partners | Outperform |
| 2024-10-02 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-02 | Downgrade | Needham | Buy → Hold |
| 2024-10-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-06-17 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-08-31 | Iniziato | BTIG Research | Buy |
| 2022-06-01 | Iniziato | Citigroup | Buy |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2021-01-11 | Iniziato | Evercore ISI | Outperform |
| 2020-11-03 | Iniziato | Citigroup | Buy |
| 2020-11-03 | Iniziato | Cowen | Outperform |
| 2020-11-03 | Iniziato | Needham | Buy |
Mostra tutto
Shattuck Labs Inc Borsa (STTK) Ultime notizie
Gap Down: Will Shattuck Labs Inc stock benefit from M AEarnings Growth Report & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Aug Wrap: Can Shattuck Labs Inc navigate macro headwinds2026 Trade Ideas & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Institution Moves: Is Shattuck Labs Inc a turnaround story2026 Bull vs Bear & Accurate Intraday Trading Signals - baoquankhu1.vn
MACD Signal: Will Shattuck Labs Inc benefit from green energy policies2026 Fundamental Recap & Target Return Focused Picks - baoquankhu1.vn
FOMO Trade: Is Shattuck Labs Inc stock a value trap2026 Levels & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aug PostEarnings: What are the risks of holding Shattuck Labs Inc2026 Trading Recap & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Shattuck Labs (STTK) to Release Earnings on Thursday - MarketBeat
Profit Recap: What is the target price for Stardust Power Inc stockEarnings Summary Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Value Recap: Is The Hershey Company stock heavily shorted2026 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
STTK Technical Analysis & ETF Price Forecast - Intellectia AI
Short Interest in Shattuck Labs, Inc. (NASDAQ:STTK) Drops By 16.5% - MarketBeat
Prosight Management Trims Stake in Shattuck Labs - National Today
Analysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH) - The Globe and Mail
Prosight Management LP Sells 1,187,740 Shares of Shattuck Labs, Inc. $STTK - MarketBeat
Shattuck Labs (STTK): Citigroup Raises Price Target to $7, Maint - GuruFocus
Citigroup Boosts Shattuck Labs (NASDAQ:STTK) Price Target to $7.00 - MarketBeat
Citi Increases Price Target for Shattuck Labs (STTK) with Potent - GuruFocus
Will Shattuck Labs Inc benefit from green energy policies2026 PreEarnings & Expert Approved Trade Ideas - baoquankhu1.vn
Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
HC Wainwright Comments on Shattuck Labs Q1 Earnings - MarketBeat
Shattuck Labs (NASDAQ:STTK) Coverage Initiated at Needham & Company LLC - Defense World
Volume Recap: Will Shattuck Labs Inc benefit from green energy policies2025 Sector Review & AI Enhanced Trading Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI) and Shattuck Labs (STTK) - The Globe and Mail
Portfolio Shifts: Is Shattuck Labs Inc stock a value trapBuy Signal & Short-Term High Return Ideas - baoquankhu1.vn
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut - AOL.com
Why Shattuck Labs Stock Soared More Than 53% Higher This Week - The Globe and Mail
Shattuck Labs, Inc. Hits New 52-Week High of $5.19 - Markets Mojo
Needham & Company LLC Begins Coverage on Shattuck Labs (NASDAQ:STTK) - MarketBeat
STTK: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Shattuck Labs stock maintained at Buy by TD Cowen on drug data - Investing.com Canada
Shattuck Labs (NASDAQ:STTK) Price Target Raised to $8.00 at Wedbush - MarketBeat
Shattuck Labs (STTK) Receives Buy Rating with $14 Target - GuruFocus
Insights into Shattuck Labs Q4 Earnings - Sahm
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights - Investing News Network
Shattuck Labs (STTK) Anticipates Strong Cash Runway Through 2029 - GuruFocus
Shattuck Labs (STTK) Reports Q4 Revenue and Clinical Trial Progr - GuruFocus
Shattuck Labs 10-K: $1.0M Revenue, $(0.70) EPS on FY Loss Improvement - TradingView
STTK: Net loss improved to $48.8M in 2025 as focus shifted to DR3 platform and cash runway extended into 2029 - TradingView
Shattuck Labs Q4 net loss narrows on lower R&D spend - TradingView
Shattuck Labs (NASDAQ: STTK) cuts 2025 R&D spend, funds operations into 2029 - Stock Titan
Shattuck Labs Advances SL-325 Clinical Trials, Reports Financial Results for Q4 and Full Year 2025 - Quiver Quantitative
BRIEF-Shattuck Labs Q4 Net Income USD -12.593 Million - TradingView
Shattuck Labs tests new Crohn’s antibody, projects cash runway into 2029 - Stock Titan
STTK SEC FilingsShattuck Labs, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Down 14.7% in February - MarketBeat
STTK Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Shattuck Labs at TD Cowen Conference: Strategic Insights in IBD Treatment - Investing.com Canada
Aug PreEarnings: Will Shattuck Labs Inc benefit from sector rotation2025 AllTime Highs & High Conviction Buy Zone Alerts - baoquankhu1.vn
STTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
STTK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Shattuck Labs Announces Participation in Upcoming March Investor Conferences - Investing News Network
Shattuck Labs Inc Azioni (STTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.04%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):